Last reviewed · How we verify
Bursitis of shoulder — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Indom | Indom | University of Trieste | Aldo-keto reductase family 1 member C4, Dehydrogenase/reductase SDR family member 9, Nicotinate phosphoribosyltransferase | |||
| indometacin | indometacin | Maastricht University Medical Center | Aldo-keto reductase family 1 member C4, Dehydrogenase/reductase SDR family member 9, Nicotinate phosphoribosyltransferase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Bursitis of shoulder
- Maastricht University Medical Center · 1 drug in Bursitis of shoulder
- University of Trieste · 1 drug in Bursitis of shoulder
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Bursitis of shoulder:
- Bursitis of shoulder treatment updates — RSS
- Bursitis of shoulder treatment updates — Atom
- Bursitis of shoulder treatment updates — JSON
Cite this brief
Drug Landscape (2026). Bursitis of shoulder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bursitis-of-shoulder. Accessed 2026-06-11.
Related
- Bursitis of shoulder full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing